ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "CRISPR-Cas9 Gene Editing for Lipids 11/11/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like triglycerides and antisense oligonucleotide. Key takeaway: CRISPR-Cas9 Gene Editing for Lipids.
Article Links:
Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. (The New England journal of medicine)
Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. (The New England journal of medicine)
Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. (The New England journal of medicine)
Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. (The New England journal of medicine)
Article 5: Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/
Featured Articles
Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211954
Summary: This meta-analysis was conducted at the individual-patient level to clarify the benefit of beta-blockers following myocardial infarction in patients with a preserved left ventricular ejection fraction of at least 50 percent. Using data from five open-label trials, the research established a robust methodology to evaluate clinical outcomes. It specifically aimed to determine the impact of beta-blocker therapy versus no therapy on a primary composite endpoint, addressing a critical area of clinical uncertainty in this patient population. This study helps establish clinical guidance for beta-blocker use after myocardial infarction in patients without significantly reduced ejection fraction.
Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211945
Summary: This phase 1 ascending-dose trial was conducted to assess the safety and efficacy of CTX310, a lipid-nanoparticle-encapsulated clustered regularly interspaced short palindromic repeats-Cas9 endonuclease targeting ANGPTL3. The rationale for this gene-editing therapy is based on observed ANGPTL3 loss-of-function genetic variants, which are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides, and a reduced lifetime risk of atherosclerotic cardiovascular disease. This study represents an important first step in investigating a novel gene-editing approach to lipid management, potentially offering a transformative therapeutic strategy for cardiovascular disease prevention. The research establishes foundational data for a promising new class of treatments aimed at modifying genetic risk factors.
Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211931
Summary: This international, open-label, randomized trial involving 1284 patients aimed to determine if successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy. Patients had undergone successful ablation at least 1 year earlier and had a C.H.A.2.D.S.2.-V.A.S.c score of 1 or more, or 2 or more for women. The study employed a blinded-outcome-assessment design to rigorously compare antithrombotic strategies. This research is crucial for optimizing post-ablation care and could significantly reduce treatment burden for patients with atrial fibrillation.
Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211925
Summary: This international, double-blind, randomized, placebo-controlled trial investigated the effect of the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab on major adverse cardiovascular events in patients without a previous myocardial infarction or stroke. While evolocumab is known to reduce major adverse cardiovascular events in patients with established atherosclerotic disease, this study expanded its evaluation to a primary prevention population with atherosclerosis. The research provides critical evidence regarding evolocumab’s potential to extend its cardiovascular benefits to patients who have not yet experienced a major cardiovascular event. This enhances understanding of evolocumab’s role in a broader spectrum of cardiovascular risk reduction.
Article 5: Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211918
Summary: Two double-blind, randomized, placebo-controlled trials, CORE-T.I.M.I. 72a and CORE2-T.I.M.I. 72b, were conducted to establish the efficacy and safety of olezarsen in patients with severe hypertriglyceridemia. Olezarsen is an antisense oligonucleotide designed to target apolipoprotein C-III messenger R.N.A., aiming to reduce triglyceride levels and, consequently, the increased risk of acute pancreatitis associated with severe hypertriglyceridemia. Patients were assigned to receive olezarsen at 50 milligrams, 80 milligrams, or placebo. This research explores a targeted therapeutic approach to address a significant unmet clinical need for reducing acute pancreatitis risk in patients with profoundly elevated triglycerides.
Transcript
Today’s date is November 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. This meta-analysis was conducted at the individual-patient level to clarify the benefit of beta-blockers following myocardial infarction in patients with a preserved left ventricular ejection fraction of at least 50 percent. Using data from five open-label trials, the research established a robust methodology to evaluate clinical outcomes. It specifically aimed to determine the impact of beta-blocker therapy versus no therapy on a primary composite endpoint, addressing a critical area of clinical uncertainty in this patient population. This study helps establish clinical guidance for beta-blocker use after myocardial infarction in patients without significantly reduced ejection fraction.
Article number two. Phase 1 Trial of C.R.I.S.P.R.-Cas9 Gene Editing Targeting ANGPTL3. This phase 1 ascending-dose trial was conducted to assess the safety and efficacy of CTX310, a lipid-nanoparticle-encapsulated clustered regularly interspaced short palindromic repeats-Cas9 endonuclease targeting ANGPTL3. The rationale for this gene-editing therapy is based on observed ANGPTL3 loss-of-function genetic variants, which are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides, and a reduced lifetime risk of atherosclerotic cardiovascular disease. This study represents an important first step in investigating a novel gene-editing approach to lipid management, potentially offering a transformative therapeutic strategy for cardiovascular disease prevention. The research establishes foundational data for a promising new class of treatments aimed at modifying genetic risk factors.
Article number three. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. This international, open-label, randomized trial involving 1284 patients aimed to determine if successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy. Patients had undergone successful ablation at least 1 year earlier and had a C.H.A.2.D.S.2.-V.A.S.c score of 1 or more, or 2 or more for women. The study employed a blinded-outcome-assessment design to rigorously compare antithrombotic strategies. This research is crucial for optimizing post-ablation care and could significantly reduce treatment burden for patients with atrial fibrillation.
Article number four. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. This international, double-blind, randomized, placebo-controlled trial investigated the effect of the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab on major adverse cardiovascular events in patients without a previous myocardial infarction or stroke. While evolocumab is known to reduce major adverse cardiovascular events in patients with established atherosclerotic disease, this study expanded its evaluation to a primary prevention population with atherosclerosis. The research provides critical evidence regarding evolocumab’s potential to extend its cardiovascular benefits to patients who have not yet experienced a major cardiovascular event. This enhances understanding of evolocumab’s role in a broader spectrum of cardiovascular risk reduction.
Article number five. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. Two double-blind, randomized, placebo-controlled trials, CORE-T.I.M.I. 72a and CORE2-T.I.M.I. 72b, were conducted to establish the efficacy and safety of olezarsen in patients with severe hypertriglyceridemia. Olezarsen is an antisense oligonucleotide designed to target apolipoprotein C-III messenger R.N.A., aiming to reduce triglyceride levels and, consequently, the increased risk of acute pancreatitis associated with severe hypertriglyceridemia. Patients were assigned to receive olezarsen at 50 milligrams, 80 milligrams, or placebo. This research explores a targeted therapeutic approach to address a significant unmet clinical need for reducing acute pancreatitis risk in patients with profoundly elevated triglycerides.
Thank you for listening. Don’t forget to subscribe.
Keywords
triglycerides, antisense oligonucleotide, C.R.I.S.P.R.-Cas9, P.C.S.K.9 inhibitor, low-density lipoprotein cholesterol, ANGPTL3, myocardial infarction, apolipoprotein C-III, left ventricular ejection fraction, evolocumab, cardiovascular outcomes, hypertriglyceridemia, antithrombotic therapy, C.H.A.2.D.S.2.-V.A.S.c score, beta-blockers, meta-analysis, major adverse cardiovascular events, atrial fibrillation, olezarsen, atherosclerosis, acute pancreatitis, gene editing, primary prevention, oral anticoagulants, catheter ablation.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post CRISPR-Cas9 Gene Editing for Lipids 11/11/25 first appeared on Cardiology Today.
Article Links:
Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. (The New England journal of medicine)
Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. (The New England journal of medicine)
Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. (The New England journal of medicine)
Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. (The New England journal of medicine)
Article 5: Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/
Featured Articles
Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211954
Summary: This meta-analysis was conducted at the individual-patient level to clarify the benefit of beta-blockers following myocardial infarction in patients with a preserved left ventricular ejection fraction of at least 50 percent. Using data from five open-label trials, the research established a robust methodology to evaluate clinical outcomes. It specifically aimed to determine the impact of beta-blocker therapy versus no therapy on a primary composite endpoint, addressing a critical area of clinical uncertainty in this patient population. This study helps establish clinical guidance for beta-blocker use after myocardial infarction in patients without significantly reduced ejection fraction.
Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211945
Summary: This phase 1 ascending-dose trial was conducted to assess the safety and efficacy of CTX310, a lipid-nanoparticle-encapsulated clustered regularly interspaced short palindromic repeats-Cas9 endonuclease targeting ANGPTL3. The rationale for this gene-editing therapy is based on observed ANGPTL3 loss-of-function genetic variants, which are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides, and a reduced lifetime risk of atherosclerotic cardiovascular disease. This study represents an important first step in investigating a novel gene-editing approach to lipid management, potentially offering a transformative therapeutic strategy for cardiovascular disease prevention. The research establishes foundational data for a promising new class of treatments aimed at modifying genetic risk factors.
Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211931
Summary: This international, open-label, randomized trial involving 1284 patients aimed to determine if successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy. Patients had undergone successful ablation at least 1 year earlier and had a C.H.A.2.D.S.2.-V.A.S.c score of 1 or more, or 2 or more for women. The study employed a blinded-outcome-assessment design to rigorously compare antithrombotic strategies. This research is crucial for optimizing post-ablation care and could significantly reduce treatment burden for patients with atrial fibrillation.
Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211925
Summary: This international, double-blind, randomized, placebo-controlled trial investigated the effect of the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab on major adverse cardiovascular events in patients without a previous myocardial infarction or stroke. While evolocumab is known to reduce major adverse cardiovascular events in patients with established atherosclerotic disease, this study expanded its evaluation to a primary prevention population with atherosclerosis. The research provides critical evidence regarding evolocumab’s potential to extend its cardiovascular benefits to patients who have not yet experienced a major cardiovascular event. This enhances understanding of evolocumab’s role in a broader spectrum of cardiovascular risk reduction.
Article 5: Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211918
Summary: Two double-blind, randomized, placebo-controlled trials, CORE-T.I.M.I. 72a and CORE2-T.I.M.I. 72b, were conducted to establish the efficacy and safety of olezarsen in patients with severe hypertriglyceridemia. Olezarsen is an antisense oligonucleotide designed to target apolipoprotein C-III messenger R.N.A., aiming to reduce triglyceride levels and, consequently, the increased risk of acute pancreatitis associated with severe hypertriglyceridemia. Patients were assigned to receive olezarsen at 50 milligrams, 80 milligrams, or placebo. This research explores a targeted therapeutic approach to address a significant unmet clinical need for reducing acute pancreatitis risk in patients with profoundly elevated triglycerides.
Transcript
Today’s date is November 11, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. This meta-analysis was conducted at the individual-patient level to clarify the benefit of beta-blockers following myocardial infarction in patients with a preserved left ventricular ejection fraction of at least 50 percent. Using data from five open-label trials, the research established a robust methodology to evaluate clinical outcomes. It specifically aimed to determine the impact of beta-blocker therapy versus no therapy on a primary composite endpoint, addressing a critical area of clinical uncertainty in this patient population. This study helps establish clinical guidance for beta-blocker use after myocardial infarction in patients without significantly reduced ejection fraction.
Article number two. Phase 1 Trial of C.R.I.S.P.R.-Cas9 Gene Editing Targeting ANGPTL3. This phase 1 ascending-dose trial was conducted to assess the safety and efficacy of CTX310, a lipid-nanoparticle-encapsulated clustered regularly interspaced short palindromic repeats-Cas9 endonuclease targeting ANGPTL3. The rationale for this gene-editing therapy is based on observed ANGPTL3 loss-of-function genetic variants, which are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides, and a reduced lifetime risk of atherosclerotic cardiovascular disease. This study represents an important first step in investigating a novel gene-editing approach to lipid management, potentially offering a transformative therapeutic strategy for cardiovascular disease prevention. The research establishes foundational data for a promising new class of treatments aimed at modifying genetic risk factors.
Article number three. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. This international, open-label, randomized trial involving 1284 patients aimed to determine if successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy. Patients had undergone successful ablation at least 1 year earlier and had a C.H.A.2.D.S.2.-V.A.S.c score of 1 or more, or 2 or more for women. The study employed a blinded-outcome-assessment design to rigorously compare antithrombotic strategies. This research is crucial for optimizing post-ablation care and could significantly reduce treatment burden for patients with atrial fibrillation.
Article number four. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. This international, double-blind, randomized, placebo-controlled trial investigated the effect of the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab on major adverse cardiovascular events in patients without a previous myocardial infarction or stroke. While evolocumab is known to reduce major adverse cardiovascular events in patients with established atherosclerotic disease, this study expanded its evaluation to a primary prevention population with atherosclerosis. The research provides critical evidence regarding evolocumab’s potential to extend its cardiovascular benefits to patients who have not yet experienced a major cardiovascular event. This enhances understanding of evolocumab’s role in a broader spectrum of cardiovascular risk reduction.
Article number five. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. Two double-blind, randomized, placebo-controlled trials, CORE-T.I.M.I. 72a and CORE2-T.I.M.I. 72b, were conducted to establish the efficacy and safety of olezarsen in patients with severe hypertriglyceridemia. Olezarsen is an antisense oligonucleotide designed to target apolipoprotein C-III messenger R.N.A., aiming to reduce triglyceride levels and, consequently, the increased risk of acute pancreatitis associated with severe hypertriglyceridemia. Patients were assigned to receive olezarsen at 50 milligrams, 80 milligrams, or placebo. This research explores a targeted therapeutic approach to address a significant unmet clinical need for reducing acute pancreatitis risk in patients with profoundly elevated triglycerides.
Thank you for listening. Don’t forget to subscribe.
Keywords
triglycerides, antisense oligonucleotide, C.R.I.S.P.R.-Cas9, P.C.S.K.9 inhibitor, low-density lipoprotein cholesterol, ANGPTL3, myocardial infarction, apolipoprotein C-III, left ventricular ejection fraction, evolocumab, cardiovascular outcomes, hypertriglyceridemia, antithrombotic therapy, C.H.A.2.D.S.2.-V.A.S.c score, beta-blockers, meta-analysis, major adverse cardiovascular events, atrial fibrillation, olezarsen, atherosclerosis, acute pancreatitis, gene editing, primary prevention, oral anticoagulants, catheter ablation.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post CRISPR-Cas9 Gene Editing for Lipids 11/11/25 first appeared on Cardiology Today.
In God we trust